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Background: Head and neck squamous cell carcinoma (HNSCC) is the 5th most common cancer worldwide.
Locally advanced HNSCC are treated with either radiation or chemo-radiotherapy, but still associated with high
mortality rate, underscoring the need to develop novel therapies. Oncolytic viruses have been garnering increasing
interest as anti-cancer agents due to their preferential killing of transformed cells. In this study, we evaluated the
therapeutic potential of mutant vesicular stomatitis virus (VSVΔ51) against the human hypopharyngeal FaDu
tumour model in vitro and in vivo.
Results: Our data demonstrated high toxicity of the virus against FaDu cells in vitro, which was associated with
induction of apoptosis. In vivo, systemic injection of 1 × 109 pfu had minimal effect on tumour growth; however,
when combined with two doses of ionizing radiation (IR; 5 Gy each) or a single injection of the vascular disrupting
agent (ZD6126), the virus exhibited profound suppression of tumour growth, which translated to a prolonged
survival in the treated mice. Concordantly, VSVΔ51 combined with ZD6126 led to a significant increase in viral
replication in these tumours.
Conclusions: Our data suggest that the combinations of VSVΔ51 with either IR or ZD6126 are potentially novel
therapeutic opportunities for HNSCC.
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Head and neck squamous cell carcinoma (HNSCC) is
the most common cancer type in the head and neck re-
gion, accounting for the 5th most common cancer
worldwide [1]. Locally advanced diseases are treated with
either radiation or chemo-radiotherapy, but are still
associated with >50% mortality rate [1,2], underscoring
the need to develop novel therapeutic strategies. Oncoly-
tic viruses have recently garnered increasing interest as
anti-cancer agents due to their preferential killing of
transformed cells (reviewed in [3,4]). Among these, the* Correspondence: Fei-Fei.Liu@rmp.uhn.on.ca
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reproduction in any medium, provided the ormutant variant of vesicular stomatitis virus (VSV) has
been evaluated in different tumour models, demonstrat-
ing promising results as either single agent or in com-
bination with other treatment modalities [5-7]. We had
previously demonstrated the exquisite sensitivity of
EBV-positive nasopharyngeal carcinoma (NPC) to a mu-
tant VSV (VSVΔ51), which has a single amino acid dele-
tion in the VSV M protein, rendering lethality to cancer
cells, whilst sparing normal cells [8]. Building upon this
observation, herein we evaluated the efficacy of VSVΔ51
against the human FaDu hypopharyngeal squamous cell
carcinoma model either as a single agent, or combined
with radiation therapy (RT) or the vascular disrupting
agent ZD6126. ZD6126 is a colchicine prodrug deriva-
tive that is metabolized in vivo to yield ZD6126 phenol,
which then selectively binds to the colchicine-bindingtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Alajez et al. Cancer Cell International 2012, 12:27 Page 2 of 6
http://www.cancerci.com/content/12/1/27site of tubulin; this disrupts the microtubule structure,
largely responsible for the structure and morphology of
dividing and immature vascular endothelial cells [9].
Our data demonstrated enhanced efficacy of VSVΔ51
when combined with either RT or ZD6126 in vivo,
thereby supporting the potential clinical utility of these
combination strategies for head and neck cancer.
Results
VSVΔ51 is lethal to FaDu cells in vitro
To evaluate sensitivity of HNSCC cells to VSVΔ51,
FaDu cells were infected with VSVΔ51 at 0.1 pfu/cell.Figure 1 VSVΔ51 is lethal to FaDu cells in vitro. (A) FaDu Cells were vis
(middle) or fluorescence microscope (right) and compared to un-infected n
24, 48, and 72 hrs post-infection with the indicated doses of VSVΔ51 alone
Data are presented as mean± SD from representative experiments, n = 3. (C
(right panel) in FaDu cells at 72 hrs post infection with 0.1 pfu/cell VSVΔ51
experiments.*p≤ 0.05.Figure 1A demonstrated significant toxicity of VSVΔ51
against FaDu cell at 72 hrs post infection (pi). Using
the MTS cell viability assay, VSVΔ51 exhibited both
dose-and time-dependent toxicity against FaDu cells
(Figure 1B, left panel), which did not change significantly
with the addition of 6 Gy ionizing radiation (IR,
Figure 1B, right panel). Using cell cycle analysis, a sig-
nificant proportion of cells underwent apoptotic cell
death at 72 hrs pi with 0.01 pfu/cell (Figure 1C, left
panel). Combining VSVΔ51 with 4 Gy IR led to a slight
increase in apoptosis (26% vs. 22%). Similarly, induction
of caspase 3 activation was observed in VSVΔ51 infectedualized at 72 hrs post-infection with VSVΔ51 (0.1 pfu/cell) using light
ormal FaDu cells (left). (B) MTS assay for FaDu cell viability at
(left) or combined with 6 Gy IR (right) delivered just before infection.
) Percent apoptosis (left panel) and fold increase in caspase 3 activity
. Data are presented as mean± SE; n = 3 from two independent
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in infected cells (Figure 1C, right panel).
Efficacy of VSVΔ51 combined with radiation therapy (RT)
or ZD6126 in established FaDu xenograft model
To determine whether the observed in vitro toxicity of
VSVΔ51 against FaDu cell could be recapitulated
in vivo, FaDu cells were implanted intramuscularly (im)
into the left leg of CD-1 nude mice. Once the leg plus
tumour diameter reached ~9 mm, the mice were rando-
mized to: a) UV-inactivated VSVΔ51; (b) local tumour
RTx2 (5 Gy each), 3 days apart; (c) VSVΔ51 alone; (d)
RT (5 Gy) plus VSVΔ51 simultaneously; then 2nd RT
(5 Gy) 3 days later; (e) ZD6126 alone; and (f ) ZD6126
just preceding VSVΔ51 injection. VSVΔ51 alone had
modest effects, whereas two doses of 5 Gy RT led to a
significant reduction in tumour growth (Figure 2A).
When combined with RT, VSVΔ51 was able to signifi-
cantly further decrease tumour growth compared to RT
alone. Interestingly, the vascular disrupting agent
ZD6126 had minimal effect on tumour growth when
administered alone, but when combined with a single
dose of VSVΔ51, a significant inhibition of tumour
growth was observed compared to either ZD6126 or
VSVΔ51 alone (Figure 2A). Although the combination
of VSVΔ51 with either RT or ZD6126 was not sufficient
to completely eradicate the tumor, these combination
led to the longest survival of tumour-bearing mice in
that the median survival increased from ~22 (for the
VSV alone group) to 48 and 47 days, respectively
(Figure 2B). While no obvious increase in viral replicationFigure 2 Efficacy of VSVΔ51 combined with RT or ZD6126 in the FaD
im in the left leg of CD-1 nude mice to allow for local RT delivery. Mice we
(1 × 109 pfu i.v.); (b) local tumour RTx2 (5 Gy), 3 days apart; (c) VSVΔ51 (1 ×
simultaneously, then 2nd RT (5 Gy) delivered 3 days later; (e) ZD6126 alone
1 × 109 VSVΔ51 i.v. Data are presented as mean leg plus tumour diameter
70 days. All p-values were calculated using the Two-Way ANOVA analysis in
comparisons were conducted using the log-rank test. n.s., not significant, *was observed in the RT plus VSVΔ51 group, images of
tumour sections removed from treated mice revealed a
significant increase in VSVΔ51 replication in the
ZD6126 plus VSVΔ51-treated group, suggesting that
the observed anti-tumour efficacy is likely attributable
to enhanced viral deposition and replication in this
group of mice (Figure 3).
Discussion
In recent years, oncolytic viruses have emerged as prom-
ising anti-cancer agents due to their demonstrated effi-
cacy in a number of preclinical models [10-13], exerting
a myriad of anti-tumour mechanisms ranging from direct
tumour cell lysis, induction of apoptosis, to targeting of
the tumour vasculature [8,14,15]. Despite these promis-
ing pre-clinical data, clinical trials utilizing oncolytic
viruses have demonstrated limited success; accentuating
the need for improvement. To that end, several studies
have administered oncolytic viruses in conjunction with
standard or targeted therapies, demonstrating enhanced
anti-tumour efficacy [16,17]. Our group has previously
reported that increased tumour interstitial fluid pressure
(IFP) could hinder therapeutic efficacy of adenoviral gene
therapy in vivo [18]. As a follow-up, we also observed
that the vascular disrupting agent ZD6126 could enhance
bio-distribution of anti-sense oligonucleotides in xeno-
grafttumours, mediated via reducing tumour IFP [19].
These two observations were hence combined, to evalu-
ate whether anti-tumour efficacy of VSVΔ51 could be
improved with the addition of ZD6126. It was gratifying
to observe that the combination of VSVΔ51 withu xenograft model. (A) FaDu xenograft tumours were established
re then randomized to six groups: a) UV-inactivated VSVΔ51
109 pfu i.v.); (d) RT (5 Gy each) plus VSVΔ51 (1 × 109 pfu i.v.)
(5 mg i.v. in 200 μl); and (f) ZD6126 (5 mg) just preceding
± S.E. (B) Mice in panel (A) were monitored for survival for up to
comparison with the UV-inactivated VSV control group; survival
p≤0.05,** p≤0.005, ***p≤0.0005.
Figure 3 Representative examples of VSVΔ51 tumour microdistribution in FaDu xenograft tumours. Viral distribution (GFP) was assessed
at 24 h post infection in relation to active vasculature (Hoechst, red). The merged field consisted of superimposed VSV, and Hoechst; the close-up
images are high-resolution representations of GFP distribution in relation to local blood vessels.
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growth, to a similar extent as that observed when VSVΔ51
was delivered in conjunction with local tumour RT
(Figure 2A and B). Furthermore, enhanced viral presence
was observed in the tumours treated with VSVΔ51 plus
ZD6126 (Figure 3). The mechanisms could relate to both
increased viral delivery consequent to tumour vasculature
disruption leading to increased leakiness, plus reduced
tumour IFP, both resulting in increased deposition and
replication of the oncolytic virus.
When VSVΔ51 was combined with local tumour RT,
enhanced viral replication was not observed, although
effective anti-tumour activity was still apparent (Figures 2
& 3). The extent of neutrophil infiltration was no differ-
ent between the tumours treated with VSVΔ51 alone, or
when combined with RT (data not shown), indicating
that innate immunity cannot explain these results of the
combination therapy. Hence, the mechanism of the add-
itional tumour suppressive effect of VSVΔ51 combined
with RT is likely an additive interaction between the
cytotoxicity of the viral oncolytic therapy, plus the direct
tumoricidal effects of ionizing radiation.
Conclusions
Enhanced efficacy of VSVΔ51 in an HNSCC tumour
model is documented when combined with either local
tumour RT, or with the use of a vascular disrupting
agent ZD2612 in vivo. These combinational regimenshave disparate mechanisms of anti-tumour efficacy, and




All animal experiments were conducted in accordance
with the guidelines of the Animal Care Committee, Uni-
versity Health Network, Toronto, Canada.
Cell lines and reagents
FaDu human hypopharyngeal carcinoma cell line was
purchased from the American Type Culture Collection
(ATCC, Manassas, VA), and was authenticated at the
Centre for Applied Genomics (the Hospital for Sick
Children, Toronto, Canada) using the AmpF/STR Identi-
filer PCR Amplification Kit (Applied BiosystemsInc, Fos-
ter City, CA). Cells were cultured in in MEM-F15
supplemented with 10% fetal bovine serum (FBS),
100 mg/L penicillin, and 100 mg/L streptomycin (RPMI-
10) at 37°C, 5% CO2. 293-F Cells were purchased from
invitrogen (Invitrogen, Carlsbad, CA).
Virus production and cell infection
VSVΔ51 carrying GFP (referred to as VSVΔ51 in this
paper) was propagated in 293-F cells as previously
described [8]. Briefly, 293-F cells were cultured in 293
SFM II medium (Invitrogen, Carlsbad, CA) in 500 mL
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GFP at MOI 0.01 in the presence of 1.8 mM CaCl2.
Supernatant was collected 16–18 hours later, filtered
through a 0.22 μm filter, then collected by centrifugation
at 18,500 g for 2.5 hrs in a Sorvall RC5 centrifuge. UV
inactivation was performed by exposing the virus for
30 min at 10 cm distance under UV light in a class II
biosafety cabinet. For cell infection, 10,000 FaDu cells
were seeded in 100 μL of MEM-F15 plus 10% FBS in a
96-well plate. Twenty-four hrs later, cells were exposed
to 0 or 6 Gy IR, medium was removed, and VSVΔ51
(MOI = 1.0-0.001) was added in 20 μL α-MEM medium.
The plates were kept at 37°C for 60 min to allow virus
attachment prior to the addition of 80 μl of normal
growth medium (MEM-F15 plus 10% FBS).
Cell viability and measurement of apoptosis
Cell viability was assessed using the MTS assay as previ-
ously described [20], and according to the manufacturer-
recommended protocol (Promega, Madison, WI). Briefly,
20 μL of the MTS reagent was added to each well in a
96-well plate at the indicated time points, and absorb-
ance was read at λ492. In order to measure the fraction
of cells in the subG0/G1 phase of cell cycle, FaDu cells
were infected with VSVΔ51 at MOI 0.1; at indicated
time points, cells were harvested, and then washed twice
in FACS buffer (PBS/0.5% BSA). Cells were re-
suspended in 1 mL of FACS buffer, then 3 mL of ice-
cold 70% ethanol was added to fix the cells for 1 hr on
ice. Cells were washed once, before re-suspending in 500
μL of FACS buffer supplemented with 40 μg/mL RNA-
seA (Sigma) and 50 μg/mL PI. Cells were incubated at
room temperature for 30 min in the dark before being
analyzed in the BD FACScalibur using FL-2A and FL-
2 W channels. CaspGlow kit (Biovision, Mountain view,
CA) was used to measure caspase 3 activity in virally-
infected FaDu cells. Briefly, infected cells were re-
suspended in 300 μL of RPMI-10 followed by the
addition of 1 μL of FITC-labeled DEVD-FMK reagent
for 45 min at 37°C to measure activated caspase 3. Fol-
lowing 45 mins’ incubation, cells were washed, re-
suspended in buffer, then analyzed in BD FACScalibur
using FL-1 channel.
Animal experiments
Five to six week old CD-1 nude male mice were pur-
chased from Charles River Laboratories (Montreal,
Canada); all experiments were conducted in accordance
with the guidelines of the Animal Care Committee, Uni-
versity Health Network. For therapeutic experiments,
3 × 106 FaDu cells were injected intramuscular (im) into
the left leg. When tumour plus leg diameter reached 8.5-
9.5 mm, treatment was initiated. Mice were treated as
indicated by injecting 1 × 109 pfu VSVΔ51 in 100 μL PBSintravenously (iv), via the tail vein. For local radiation
treatments, mice were immobilized in a Lucite box, and
the tumor-bearing leg was exposed to 225 kVp (13 mA)
at a dose rate of 3.37 Gy/min using an X-ray irradiator
C (X-RAD 225; Precision X-ray). ZD6126 (AstraZeneca)
treatment was delivered as previously described [18].
Briefly, ZD6126 was dissolved in 10% sodium carbonate
and 90% PBS (pH 7.4, 25 mg/mL). A single 200 μL injec-
tion of ZD6126 solution was injected i.p. into FaDu–
bearing nude mice. For the combined treatment, mice
were treated with ZD6126 and then immediately
injected with 1 × 109 pfu VSVΔ51 in 100 μL PBS intra-
venously (iv), via the tail vein. Tumor growth was moni-
tored by measuring tumor plus leg diameter as
described before [21].
Microdistribution studies
FaDu xenograft tumours were established and treated as
described above. At 24 hrs post-VSV injection, Hoechst
33342 (600 μg in 100 μL PBS) was injected iv for
visualization of the active vasculature [22]; the mice
were sacrificed 1 min later. Tumours were immediately
excised, frozen in Optimal Cutting Temperature (OCT)
compound (Bayer Corporation, USA), then stored at
−80°C. Serial sections (5 μm thickness) were cut through
each tumour at three levels, 500 μm apart. The slides
were scanned using fluorescence microscopy to visualize
GFP-expression and Hoechst 33342 perfusion. All stain-
ing and cryosectioning procedures were performed by
Pathology Research Program Services, University Health
Network (Toronto, Canada).
Microscopy
Slides were imaged at 10X magnification using an Olympus
BX50 (Olympus, Japan) tiling fluorescence stereomicro-
scope (FITC/GFP: λEx =482 nm, λEm=535 nm, 500 ms ex-
posure; Hoechst 33342: λEx =360 nm, λEm=460 nm,
100 ms exposure). Images were captured using ImagePro
5.1 (Media Cybernetics, USA). Fluorescence microscopy
images were imported into Adobe Photoshop and merged
into a composite image, where the red, and green channels
corresponded to Hoechst 33342 (active vasculature), and
GFP (VSV infection), respectively.
Statistical analysis
Statistical analysis and graphing were performed using
Microsoft Excel 2010, and Graphpad Prism 5.0 software.
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